Optimizing Hepatitis C Virus (HCV) Treatment in a US Colocated HCV/Opioid Agonist Therapy Program.

Habchi, Jackie; Thomas, Aurielle M; Sprecht-Walsh, Sophie; Arias, Elenita; Bratberg, Jeffrey; Hurley, Linda; Hart, Susan; Taylor, Lynn E

Habchi, Jackie; Thomas, Aurielle M; Sprecht-Walsh, Sophie; Arias, Elenita; Bratberg, Jeffrey; Hurley, Linda; Hart, Susan; Taylor, Lynn E.

Afiliação

Habchi J; CODAC Behavioral Healthcare, Providence, Rhode Island, USA.
Thomas AM; University of Rhode Island, Providence, Rhode Island, USA.
Sprecht-Walsh S; CODAC Behavioral Healthcare, Providence, Rhode Island, USA.
Arias E; CODAC Behavioral Healthcare, Providence, Rhode Island, USA.
Bratberg J; University of Rhode Island, Providence, Rhode Island, USA.
Hurley L; CODAC Behavioral Healthcare, Providence, Rhode Island, USA.
Hart S; CODAC Behavioral Healthcare, Providence, Rhode Island, USA.
Taylor LE; CODAC Behavioral Healthcare and University of Rhode Island, Providence, Rhode Island, USA.

Open Forum Infect Dis ; 7(10): ofaa310, 2020 Oct.

Article em En | MEDLINE | ID: mdl-33072802

Palavras-chave

colocated care; direct-acting antivirals (DAAs); hepatitis C virus infection (HCV); opioid agonist therapy (OAT); people who inject drugs (PWID)

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Open Forum Infect Dis Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google